118 related articles for article (PubMed ID: 2116055)
1. [Use of OKT-3 in treatment of rejection following kidney transplantation].
Hansen C; Müller P; Seibt F; Oesterwitz H; May G; Strobelt V; Kaden J; Ditscherlein G; Scholz D
Z Urol Nephrol; 1990 Apr; 83(4):165-70. PubMed ID: 2116055
[TBL] [Abstract][Full Text] [Related]
2. [OKT 3 treatment of kidney transplant recipients].
Zlabinger GJ; Ulrich W; Pohanka E; Kovarik J
Wien Klin Wochenschr; 1990 Mar; 102(5):142-7. PubMed ID: 2108521
[TBL] [Abstract][Full Text] [Related]
3. The treatment of steroid-resistant renal allograft rejection with OKT3 and plasmapheresis.
Haberal M; Sert S; Gülay H; Arslan G; Bilgin N
Transplant Proc; 1990 Aug; 22(4):1761-3. PubMed ID: 2117801
[No Abstract] [Full Text] [Related]
4. [Treatment of kidney graft rejection with a monoclonal antibody (Orthoclone OKT-3)].
Ladefoged SD; Friedberg M; Glenthøj A
Ugeskr Laeger; 1988 Nov; 150(48):2974-6. PubMed ID: 3144080
[No Abstract] [Full Text] [Related]
5. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
Shield CF; Hughes JD
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
[TBL] [Abstract][Full Text] [Related]
6. Treatment with OKT3 and cyclosporine for acute allograft rejection.
Schulak JA; Mayes JT; Hricik DE
Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150
[TBL] [Abstract][Full Text] [Related]
7. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
8. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation.
Hooks MA; Wade CS; Millikan WJ
Pharmacotherapy; 1991; 11(1):26-37. PubMed ID: 1902291
[TBL] [Abstract][Full Text] [Related]
9. Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.
McLigeyo SO; Notghi A; Anderton JL; Dick J
East Afr Med J; 1990 Sep; 67(9):667-73. PubMed ID: 2123786
[TBL] [Abstract][Full Text] [Related]
10. Orthoclone OKT3 as rescue treatment for steroid-resistant and recurrent acute rejection in clinical renal transplantation.
Tvedegaard E; Olgaard K
Transplant Proc; 1990 Feb; 22(1):217-8. PubMed ID: 2106738
[No Abstract] [Full Text] [Related]
11. OKT 3: nursing considerations for use in acute renal transplant rejection.
Trusler LA
ANNA J; 1990 Aug; 17(4):299-303. PubMed ID: 2118750
[TBL] [Abstract][Full Text] [Related]
12. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
13. Uses of orthoclone OKT3 for prophylaxis of rejection and induction in initial nonfunction in kidney transplantation.
Kahana L; Ackermann J; Lefor W; Weinstein S; Wright C; DeQuesada A; Alveranga D; Baxter J; Shires D
Transplant Proc; 1990 Aug; 22(4):1755-8. PubMed ID: 2117799
[TBL] [Abstract][Full Text] [Related]
14. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
Light JA; Khawand N; Aquino A; Ali A; Korb S
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
[TBL] [Abstract][Full Text] [Related]
15. Treating cardiac allograft rejection: present approach--analysis of 100 consecutive patients.
Radovancevic B; Birovljev S; Frazier OH
J Heart Transplant; 1990; 9(3 Pt 2):288-91. PubMed ID: 2113091
[TBL] [Abstract][Full Text] [Related]
16. Histologic findings and kidney graft outcome in patients with steroid-resistant rejections before and after OKT3 therapy.
Niebel W; Metz KA; Albrecht KH; Wagner K; Kribben A; Erhard J; Eigler FW
Transplant Proc; 1990 Aug; 22(4):1764. PubMed ID: 2117802
[No Abstract] [Full Text] [Related]
17. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
[TBL] [Abstract][Full Text] [Related]
18. Preliminary results of a prospectively randomized trial of ALG vs OKT3 for steroid-resistant rejection after renal transplantation in the early postoperative period.
Hesse UJ; Wienand P; Baldamus C; Arns W
Transplant Proc; 1990 Oct; 22(5):2273-4. PubMed ID: 2120814
[No Abstract] [Full Text] [Related]
19. Successful use of Orthoclone OKT 3 for steroid-resistant acute rejection in pediatric renal allograft recipients.
Palmer J; Slook P
ANNA J; 1992 Aug; 19(4):375-7. PubMed ID: 1520028
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
Barr ML; Sanchez JA; Seche LA; Schulman LL; Smith CR; Rose EA
Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
